Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy

NCT00637845 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00637845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00637845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2002
Completion date
February 28, 2003
Enrollment
248 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease, heartburn